DAYBUE (trofinetide) — Topline data
Sep–Nov 2026
Accelerated enrollment in the trofinetide clinical trial in Japan, with topline results now anticipated in the September to November 2026 timeframe.Source filing
ACAD biotech catalysts & pipeline
ACADIA PHARMACEUTICALS INC · Data as of 2026-10-25
Upcoming catalysts
ACP-211 — Topline data
Q3 2027
In the fourth quarter of 2025 we initiated a Phase 2 study of ACP-211 in MDD and expect to report top-line results sometime between the second and third quarters of 2027.Source filing
remlifanserin — Conference presentation
Nov 16–Nov 19
Acadia plans to present detailed safety and efficacy results from the RADIANT Phase 2 study in an oral presentation at the upcoming Clinical Trials on Alzheimer's Disease (CTAD) conference, taking place November 16-19, 2026 in Boston.Source filing